The forest plots of pooled estimates of standardized mean differences of circulating apelin (A), apelin/HDL-c (B), apelin/LDL-c (C), apelin/triglycerides (D), and apelin/total chol... by Hamed Akbari (8119361)

Subjects:

The number of gauging cross-sections where a statistically significant decreasing trend was identified. by Krzysztof Kochanek (835532)

Mean decrease Gini score by Tweet and user characteristics. by Gray Babbs (16648894)

Decrease of the mean number of natural teeth and POPs with age. by Sul-Hee Kim (11873853)

Base-case results. by Ping Chen (89712)

The base case analysis. by Wenwang Lang (20293527)

“…</p><p>Results</p><p>In the base-case scenario, adding benmelstobart and anlotinib to chemotherapy increased QALYs by 0.34 at an additional cost of $24,684.07, yielding an ICER of $71,559.84 per QALY. …”

Base-case results. by Shuo Kang (1306860)

“…One-way and probabilistic sensitivity analyses were conducted to estimate the robustness of the model results,</p><p>Results</p><p>In base-case analysis, compared with toripalimab plus chemotherapy and chemotherapy alone, ITH-testing directed therapy could bring additional 0.14 QALYs and 0.29 QALYs, with marginal costs of $3750.75 and $7778.18, resulting in the ICER of $27,353.27/QALY and $26,461.46/QALY, respectively, which lower than the Chinese willingness-to-pay (WTP) threshold. …”

Base-case results. by Mingxi Xie (19812594)

“…The model time-frame was one-year. Base-case analysis and sensitivity analysis were performed. …”

Base-case analysis. by Akiko Kowada (14659965)

“…The willingness-to-pay (WTP) threshold was set at US$50,000 per QALY gained. In the base-case analysis, HTLV-1 antenatal screening (US$76.85, 24.94766 QALYs, 24.94813 LYs, ICER; US$40,100 per QALY gained) was cost-effective compared with no screening (US$2.18, 24.94580 QALYs, 24.94807 LYs). …”

The percentage of significant partial correlations (with sign matching interaction in either direction), as recovered from the base case model. by Susanne Pinto (13767952)

Deterministic result of the base-case analysis. by Sudewi Mukaromah Khoirunnisa (15288505)

“…Efficacy data and baseline characteristics in the base-case analysis were primarily derived from the 11-year results of the HERA trial. …”

Base-case estimated number of patients categorised in different phenotypes and age groups and their base-case cost of management. by Siew Chin Ong (9314213)

Base-case results (deterministic analysis). by Robert Hodgson (2026294)

Base-case results: Probabilistic analysis. by Robert Hodgson (2026294)

Transepithelial resistance of NHBE decreases significantly after PAA exposure. by Ellie S. Burns (21246537)

Descriptive data for the simulated population (base-case scenario). by Jacek A. Kopec (8519922)

Significant genes identified in the gene-based test with GWAS summary data. by Samantha Gonzales (8798435)

Input values and distributions used in the base case and sensitivity analysis. by Afschin Gandjour (342184)

Pairs of clusters that were significantly different from each other based on the layer profile of their cases. by Lauren S. Richardson (16841643)

“…<p>Pairs of clusters that were significantly different from each other based on the layer profile of their cases.…”

Vibriocidal activities were significantly decreased by depletion of IgM in serum. by Jae Seung Yang (701319)